Orgenesis's change in inventory for the quarter that ended in Dec. 2021 was $0.01 Mil. It means Orgenesis's inventory
declined by $0.01 Mil
from Sep. 2021 to Dec. 2021 .
Orgenesis's change in inventory for the fiscal year that ended in Dec. 2021 was $0.06 Mil. It means Orgenesis's inventory
declined by $0.06 Mil
from Dec. 2020 to Dec. 2021 .
Orgenesis's Total Inventories for the quarter that ended in Dec. 2021 was $0.12 Mil.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Orgenesis's Days Inventory for the quarter that ended in Dec. 2021 was 1.37.
Total Inventories can be measured by Days Sales of Inventory (DSI).
Orgenesis's days sales of inventory (DSI) for the quarter that ended in Dec. 2021 was 1.66.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Orgenesis's Inventory Turnover for the quarter that ended in Dec. 2021 was 66.61.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orgenesis's Inventory-to-Revenue for the quarter that ended in Dec. 2021 was 0.02.
Orgenesis Change In Inventory Historical Data
The historical data trend for Orgenesis's Change In Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Orgenesis Annual Data
Trend
Nov12
Nov13
Nov14
Nov15
Nov16
Nov17
Nov18
Dec19
Dec20
Dec21
Change In Inventory
-0.27
-0.93
-0.41
-0.08
0.06
Orgenesis Quarterly Data
Feb17
May17
Aug17
Nov17
Feb18
May18
Aug18
Nov18
Mar19
Jun19
Sep19
Dec19
Mar20
Jun20
Sep20
Dec20
Mar21
Jun21
Sep21
Dec21
Change In Inventory
0.01
-0.02
0.03
0.03
0.01
Orgenesis Change In Inventory Calculation
Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.
Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.06 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis (NAS:ORGS) Change In Inventory Explanation
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Orgenesis's Days Inventory for the quarter that ended in is calculated as:
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Orgenesis's Inventory to Revenue for the quarter that ended in Dec. 2021 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Orgenesis Change In Inventory Related Terms
Thank you for viewing the detailed overview of Orgenesis's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.
Orgenesis Inc is a part of the healthcare sector. It is a fully-integrated biopharmaceutical company focused on developing trans-differentiation technologies for diabetes and vertically integrating manufacturing that can optimize its abilities to scale-up its technologies for clinical trials and eventual commercialization. The group operates in two segments namely CDMO and POC. The company is also engaged in applying its disciplined execution to emerging technologies of other cell therapy markets in such areas as cell-based cancer immunotherapies and neurodegenerative diseases.
My Portfolios
Create New Portfolio
Portfolio Contest
My Gurus
Personalize
Premium Gurus 
0(0%) Volume: 130,258 9:40AM EDT
Email Alerts
Stock PDF
RSS
Website
Filings
Download
Manual of Stocks™ Web APP
NAS:ORGS has been successfully added to your 
